

Complete Manuscript Title:

**Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms**

Short Running Head:

COVID-19 Vaccines and Otologic Symptoms

Authors:

Ramsi A. Woodcock, JD, MSc\*  
Assistant Professor  
University of Kentucky Rosenberg College of Law  
Secondary Appointment  
Department of Management  
University of Kentucky Gatton College of Business & Economics  
Law Building  
620 S. Limestone  
Lexington, KY 40506  
United States of America  
Office Phone: +1-859-257-1253  
Cell Phone (preferred): +1-646-385-3592  
Email: rwo236@uky.edu

Loren J. Bartels MD, FACS\*\*  
Director, Tampa Bay Hearing and Balance Center  
Clinical Professor of Otolaryngology  
University of South Florida College of Medicine  
5 Tampa General Circle 610  
Tampa, FL 33606  
United States of America  
Office Phone: +1-813-315-4327  
Email: lbartels@tampabayhearing.com

Sources of Support/Disclosure of Funding:

This study received no outside support or funding.

Conflicts of Interest:

Ramsi A. Woodcock suffers from otologic symptoms that he believes to have been caused by COVID-19 vaccination. He is Loren J. Bartels' patient.

\*Contribution: conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; software; supervision; validation; visualization; writing—original draft; writing—review & editing. *This author is not a medical doctor. His contributions to this paper are not intended to be, nor should they be taken as, medical advice.*

\*\*Contribution: methodology; writing—review & editing.

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## *COVID-19 Vaccines and Otologic Symptoms*

1

### ABSTRACT

2 **Hypothesis:** This study investigates whether U.S. Centers for Disease Control and Prevention  
3 Vaccine Adverse Events Reporting System (VAERS) data suggest an association between  
4 vertigo, tinnitus, hearing loss, Bell's palsy and the COVID-19 vaccines administered in the  
5 United States.

6 **Background:** Published case reports suggest a possible association between various otologic  
7 symptoms and the COVID-19 vaccines, but the only published analysis of VAERS data, which  
8 did not account for underreporting of late-appearing adverse events, found no association  
9 between hearing loss and the vaccines.

10 **Methods:** The incidence in VAERS of vertigo, tinnitus, hearing loss, and Bell's palsy associated  
11 with COVID-19 vaccinations administered between December 14, 2020 and June 7, 2021 was  
12 compared with published rates for the general population. To account for underreporting of late-  
13 appearing adverse events, incidences were calculated using only the initial part of the  
14 observation period, during which reported events spike above expected events.

15 **Results:** The COVID-19 vaccines were associated with statistically significant increases in the  
16 incidence of vertigo, tinnitus, hearing loss, and Bell's palsy of 1877, 50, 12, and 14 cases per  
17 100,000, respectively. In relation to the mRNA-1273 or BNT162b2 vaccines, the Ad26.COV2.S  
18 vaccine was associated with a statistically significant excess incidence of vertigo, tinnitus, and  
19 hearing loss of at least 723, 57, and 55 cases per 100,000, respectively.

20 **Conclusion:** These results suggest an association between the COVID-19 vaccines and vertigo,  
21 tinnitus, hearing loss, and Bell's palsy. They also suggest that, with respect to vertigo, tinnitus,  
22 and hearing loss, the association is relatively strong for the Ad26.COV2.S vaccine.

## *COVID-19 Vaccines and Otologic Symptoms*

23

### I. INTRODUCTION

24       Published case reports suggest a possible association between the COVID-19 vaccines and  
25 various otologic symptoms, including hearing loss, tinnitus, and vertigo.<sup>1-3</sup> However, the only  
26 preliminary study of otologic symptoms in U.S. Centers for Disease Control and Prevention  
27 Vaccine Adverse Event Reporting System (VAERS) data published to date, in which Formeister  
28 et al. investigated reports of hearing loss, failed to find an association.<sup>4,5</sup> This may be because  
29 vaccine adverse event reports relate to a single trigger—vaccination—whereas the population  
30 incidence rates to which they must be compared relate to multiple triggers.<sup>6</sup> For example, the  
31 population incidence of vertigo includes cases of vertigo due to trauma, viral infection, and genetic  
32 disorders, among other things, whereas doctors and patients likely tend to report to VAERS only  
33 cases of vertigo that they believe to be triggered by vaccination. As a result, the incidence rate of  
34 vertigo in the VAERS reports will be lower than the population incidence rate unless vaccination  
35 triggers more vertigo than all other triggers combined.

36       The U.S. Centers for Disease Control and Prevention (CDC) tries to address this problem by  
37 encouraging doctors and patients to report all symptoms they encounter after vaccination.<sup>7</sup> In  
38 theory, that should ensure that symptoms due to all triggers, including vaccination, are reported,  
39 with the result that, if vaccination triggers additional cases of a particular symptom, then the  
40 incidence rate in the VAERS reports will be higher than the population incidence rate and  
41 researchers will be able to infer from this difference that there is an association between the  
42 symptom and vaccination.

43       Unfortunately, doctors and patients do not heed the CDC. As Figure 1 shows, VAERS reports  
44 for all vaccines, COVID or otherwise, decline dramatically as the date of onset of the reported

### *COVID-19 Vaccines and Otologic Symptoms*

45 symptom extends beyond the vaccination date. If doctors and patients were to report all symptoms  
46 based on all triggers, including post-vaccination triggers, one would expect the line to be  
47 approximately flat, unless vaccination is a disproportionate source of all symptoms experienced  
48 by the population due to any cause, which is unlikely. In the absence of any test enabling doctors  
49 and patients to determine whether a particular symptom is caused by vaccination, doctors and  
50 patients rely on proximity of the date of symptom onset to the date of vaccination as a proxy for  
51 causation, which explains why, in Figure 1, reports spike for symptoms with onset immediately  
52 after vaccination and then fall off almost to zero after a few weeks.<sup>8</sup> As shown in Figure 3, VAERS  
53 reports for the symptoms considered in this study—vertigo, tinnitus, hearing loss, and Bell’s  
54 palsy—all exhibit a similar initial spike in reported symptoms with onset immediately after  
55 vaccination, followed by a precipitous decline in reported symptoms as the date of onset moves  
56 farther away from the date of vaccination.

57 One way around the failure of doctors and patients fully to report symptoms due to non-  
58 vaccine triggers would be to use published reporting sensitivity rates to inflate the raw number of  
59 VAERS reports. Unfortunately, existing studies of VAERS reporting sensitivity, such as that of  
60 Miller et al., are based on VAERS reports that have been selected for their temporal proximity to  
61 vaccination—the same filter that doctors and patients place on their own reporting—and hence  
62 are unlikely fully to capture underreporting of symptoms associated with non-vaccine triggers.<sup>9</sup>  
63 Sensitivity rates extrapolated from a comparison with clinical trial adverse event reports suffer  
64 from a similar limitation, because clinical trials solicit reports only within a few days of  
65 vaccination.

66 Fortunately, there is another way around the underreporting of non-vaccine-triggered events.

### *COVID-19 Vaccines and Otologic Symptoms*

67 If the number of cases reported during the peak reporting period immediately after vaccination—  
68 the “spike period”—exceeds the number of cases expected during that period based on the  
69 population incidence rate of the symptom, then it follows that the vaccine is a trigger of the  
70 symptom, even if reported cases fall below expected cases for the rest of the observation period,  
71 and even if the incidence rate implied by the reports, if calculated over the entire observation  
72 period, is below the population incidence rate. For the only way in which reported cases can  
73 exceed expected cases during any part of an observation period, despite underreporting of cases  
74 due to non-vaccine triggers, is if vaccine-triggered cases of the symptom are numerous enough  
75 over that period to make up the difference. But the existence of any number of vaccine-triggered  
76 cases, if statistically significant in magnitude, is sufficient to establish an association between the  
77 vaccine and the symptom.

78 Consider a numerical illustration. Suppose that vaccination triggers one hundred excess cases  
79 of vertigo in the first day after vaccination and none on the second day, and that all other triggers  
80 cause an additional hundred cases every day, but that doctors and patients, despite reporting all  
81 symptoms on the first day regardless of trigger, report none on the second day, because they  
82 assume that none of the day-two symptoms are triggered by the vaccine. If 365,000,000  
83 vaccinations are observed, then for a 2-day observation period, the incidence of vertigo is 10 (per  
84 100,000 person-years, as with all incidence rates discussed in the present study), but the population  
85 incidence (which is based on the number of cases caused by all other triggers) is 15, suggesting,  
86 falsely, that there is no association between vaccination and the symptom. If, however, one  
87 considers only the first day, during which total reported cases of 200 spike above expected cases  
88 of 100, then the incidence is 20, which exceeds the population incidence of 15 and therefore

## *COVID-19 Vaccines and Otologic Symptoms*

89 correctly indicates the existence of an association.

90 An additional consideration complicates analysis of spike periods: reports may not be  
91 accurate. As a result, the presence of a spike in raw report numbers for a particular symptom is  
92 not sufficient to suggest the existence of an association between the vaccine and the symptom.  
93 The spike must be discounted, either through examination of individual reports or by a rate of  
94 accuracy derived from analysis of past reports. Even if discounting eliminates the spike, however,  
95 the analysis does not end, because the studies, such as that of Miller et al., that provide sensitivity  
96 rates for reporting of adverse events with onset close to the date of vaccination are likely to capture  
97 underreporting during spike periods even if they do not capture underreporting of cases  
98 thereafter.<sup>9</sup> The same is true for sensitivity rates extrapolated from a comparison with clinical trial  
99 reports. Published sensitivity rates and those extrapolated from clinical trials can therefore be used  
100 to offset the accuracy discount with a multiplier that accounts for underreporting during the spike.

## 101 II. MATERIALS & METHODS

102 To investigate the relationship between the COVID vaccines administered in the United States  
103 (Moderna's mRNA-1273, Pfizer-BioNTech's BNT162b2, and Johnson & Johnson's  
104 Ad26.COV2.S) and otologic symptoms, analysis of spikes in reports to VAERS of vertigo,  
105 tinnitus, hearing loss, and Bell's palsy over expected levels were carried out. To avoid bias  
106 associated with the ongoing arrival of new reports regarding the COVID-19 vaccines, the analysis  
107 was limited to vaccines administered between December 14, 2020 and June 7, 2021, to symptoms  
108 with an onset within 30 days of vaccination, and to reports made within 60 days of vaccination.  
109 The MedDRA-coded symptom fields in the VAERS database were searched for "vertigo,"  
110 "tinnitus," "hearing loss," "bell's palsy," and synonyms, and the results filtered for the

### *COVID-19 Vaccines and Otologic Symptoms*

111 “COVID19” vaccine type to create datasets for each symptom. Table 1 and Figure 2 provide more  
112 information on the search terms, datasets, and study parameters.

113 Formeister et al. manually reviewed each VAERS adverse event report in their study sample  
114 for accuracy. For the present study of multiple symptoms relating to nearly seven months of  
115 vaccinations, as opposed to the study of a single symptom over 2.5 months carried out by  
116 Formeister et al., manual verification could not be undertaken. Instead, a best-guess accuracy rate  
117 was identified by running the same search of the VAERS data for hearing loss reported by  
118 Formeister et al. and using the resulting case count of 475 to extrapolate an accuracy rate of 8%  
119 from Formeister et al.’s conclusion that only 40 reported cases in their VAERS data were accurate.  
120 This appears to be a very low accuracy rate. By contrast, an accuracy rate of 57% is implied by  
121 the work of Su et al. on anaphylaxis reports to VAERS in relation to a number of non-COVID-19  
122 vaccines.<sup>10</sup>

123 A reporting sensitivity rate of 30%, corresponding to a multiplier of 3.3, was used for tinnitus,  
124 hearing loss, and Bell’s palsy. This rate was obtained by averaging the rates reported by Miller et  
125 al. for reports of anaphylaxis and Guillain-Barré syndrome associated with non-COVID-19  
126 vaccinations.<sup>9</sup> It is somewhat lower than the 50% sensitivity rate that appears to have been  
127 arbitrarily chosen for sensitivity testing of hearing loss reports by Formeister et al.

128 A much lower sensitivity rate—0.6%, corresponding to a multiplier of 166.9—was used for  
129 vertigo, because, as Neuhauser has pointed out, vertigo is common in the general population,  
130 affecting between 20% and 30% of adults.<sup>11</sup> Doctors and patients may therefore be less likely to  
131 report vertigo in connection with the COVID-19 vaccines than they are to report tinnitus, hearing  
132 loss, or Bell’s palsy, each of which is rare in comparison.<sup>11</sup> To identify an appropriate reporting

### *COVID-19 Vaccines and Otologic Symptoms*

133 sensitivity rate for vertigo, the incidence of other common symptoms—pain, erythema, swelling,  
134 fever, headache, fatigue, myalgia, and nausea or vomiting—reported in the COVID-19 vaccines’  
135 Phase III clinical trials was compared with the incidence of the same symptoms in the VAERS  
136 reports and the largest result—that for fever—was used to obtain the 0.6% reporting sensitivity  
137 rate.<sup>12–14</sup> A comparison with clinical trial reports was considered probative of the true reporting  
138 sensitivity rate during the spike period because clinical trial administrators solicit reports from  
139 trial subjects within seven days of vaccination.<sup>12–14</sup>

140 Spike periods were determined after application of the 8% accuracy discount and the  
141 applicable underreporting multiplier to the VAERS report counts for each symptom. As shown in  
142 Figure 3 and discussed more fully in the Results section, the spike period was two days each for  
143 vertigo, tinnitus, and Bell’s palsy, and one day for hearing loss. The statistical significance of the  
144 incidence rate of each symptom over its spike period, in relation to the published population  
145 incidence rate for the symptom, was determined using the normal approximation to the binomial  
146 distribution for one-sample inference with two tails.<sup>15–18</sup>

147 The proportional reporting ratio (PRR),<sup>19</sup> which compares the incidence rate of symptoms in  
148 reports related to the vaccine at issue (here, the COVID-19 vaccines) to the rate of all other  
149 symptoms in all other VAERS reports,<sup>20</sup> was also calculated for all four symptoms. The PRR has  
150 two helpful features. First, it compares VAERS data with other VAERS data, so the problem of  
151 comparing single-trigger VAERS incidence rates to multiple-trigger population incidence rates is  
152 avoided. Second, the PRR provides a useful check on the appropriateness of the accuracy and  
153 reporting sensitivity rates used in the present study, because, if accuracy and reporting sensitivity  
154 rates are constant across all vaccines, then these rates cancel out of the PRR, making the PRR



### *COVID-19 Vaccines and Otologic Symptoms*

155 invariant in reporting accuracy and sensitivity assumptions. The statistical significance of the  
156 PRRs, in relation to the null hypothesis of one (i.e. that there is no difference between the  
157 incidence of the symptom in COVID-19 vaccine reports and the incidence of all other symptoms  
158 in all other vaccine reports) was determined using the chi-squared test with one degree of freedom.

159 Finally, to investigate the relative association of different COVID-19 vaccines with vertigo,  
160 tinnitus, hearing loss, and Bell's palsy, VAERS spike-period case counts, discounted as above,  
161 were categorized by vaccine manufacturer, incidence rates for each were calculated using CDC  
162 data on total administered vaccine doses per manufacturer, and, for each symptom, the normal  
163 approximation to the binomial distribution for two-sample inference was applied with two tails.  
164 For all three tests, p-values below 0.05 were considered significant.

165 University of Kentucky determined that this study is exempt from institutional review board  
166 approval because the study uses deidentified data publicly available on the CDC website.

### 167 III. RESULTS

168 Figure 3 shows the distribution of cases, after adjustment for accuracy and underreporting, in  
169 terms of time to symptom onset, including the spike period for each symptom. The incidence rate  
170 of vertigo in the VAERS reports over vertigo's two-day spike period was 3,277 (per 100,000  
171 person-years, as for all incidence rates reported here), significantly in excess of the population  
172 incidence of vertigo of 1,400 reported by Neuhauser et al. ( $p < 0.00001$ ).<sup>17</sup> The incidence rate of  
173 tinnitus in the VAERS reports over tinnitus's two-day spike period was 104, significantly in  
174 excess of the population incidence of tinnitus of 54 reported by Martinez et al. ( $p < 0.00001$ ).<sup>16</sup>  
175 The incidence rate of hearing loss in the VAERS reports over hearing loss's one-day spike period  
176 was 39, significantly in excess of the population incidence of hearing loss of 27 reported by

### *COVID-19 Vaccines and Otologic Symptoms*

177 Alexander et al. ( $p < 0.00001$ ).<sup>18</sup> The incidence rate of Bell's palsy in the VAERS reports over  
178 Bell's palsy's two-day spike period was 37, significantly in excess of 23, which is the average of  
179 the population incidence rates for Bell's palsy referenced by Ozonoff et al. ( $p < 0.00001$ ).<sup>15</sup> As  
180 Table 2, which reports these results, shows, incidence rates calculated using the three-week  
181 observation period employed by Formeister et al., rather than the spike periods, were, by contrast,  
182 all lower than their respective population incidence rates, by 846 for vertigo, 36 for tinnitus, 22  
183 for hearing loss, and 14 for Bell's palsy. Incidence rates in the VAERS reports break even with  
184 population incidence rates at approximately a one-week observation period.

185 The results for vertigo and tinnitus were robust to lower underreporting multipliers. As Table  
186 2 also reports, a statistically significant excess incidence of tinnitus remained after reduction of  
187 the underreporting multiplier from 3.3 to the value of 2 used by Formeister et al., and a statistically  
188 significant excess incidence of vertigo remained after the underreporting multiplier was scaled  
189 down in the same proportion (i.e., by the ratio of 2 to 3.3).

190 The PRRs, which require no assumption regarding the rate of accuracy or the rate of reporting  
191 sensitivity, were, for vertigo, tinnitus, hearing loss, and Bell's palsy, 4.76, 5.41, 2.63, and 1.46,  
192 respectively, as shown in Table 3. Those for vertigo and tinnitus exceeded the null hypothesis of  
193 one to a statistically significant degree ( $p < 0.001$  for vertigo and  $p < 0.0001$  for tinnitus). This  
194 result was consistent with the robustness of the spike period results for vertigo and tinnitus.

195 These results were clinically significant. As Table 2 shows, over the course of the two-day  
196 spike period after vaccination, 30,761 of the 171 million people who received at least one dose of  
197 vaccine in the United States during the study period (about 1 per 5,569 persons receiving at least  
198 one dose) are estimated to have had vertigo. That was 17,619 more cases than the 13,142 cases

### *COVID-19 Vaccines and Otologic Symptoms*

199 that were expected over that period based on the population incidence of vertigo (an excess rate  
200 of 1 per 9,723 persons receiving at least one dose). For tinnitus, the excess of reported cases over  
201 expected cases over the two-day tinnitus spike period was 466 (an excess rate of 1 per 367,579  
202 persons receiving at least one dose). For hearing loss, it was 58 excess cases over the one-day  
203 hearing loss spike period (about 1 per 2.94 million persons receiving at least one dose), and for  
204 Bell's palsy it was 130 excess cases over the two-day Bell's palsy spike period (about 1 extra  
205 Bell's palsy case per 1.32 million persons receiving at least one dose).

206 Table 4 sets forth the results regarding the relative associations of the three vaccines  
207 administered in the United States. The incidence of vertigo associated with the Ad26.COV2.S  
208 vaccine in the VAERS reports was 4,258, in excess of the incidence of 3,535 associated with the  
209 mRNA-1273 vaccine and the incidence of 2,947 associated with the BNT162b2 vaccine. The  
210 excess in the incidence of vertigo associated with the Ad26.COV2.S vaccine in relation to both  
211 the mRNA-1273 vaccine and the BNT162b2 vaccine was statistically significant ( $p < 0.00001$ ),  
212 as was the excess in the incidence of vertigo associated with the mRNA-1273 vaccine in relation  
213 to the BNT162b2 vaccine ( $p < 0.00001$ ). The incidence of tinnitus associated with the  
214 Ad26.COV2.S vaccine in the VAERS reports was 157, in excess of the incidence of 100 associated  
215 with both the mRNA-1273 and BNT162b2 vaccines to a statistically significant degree ( $p < 0.001$   
216 and  $p < 0.0001$ , respectively). The incidence of hearing loss associated with the Ad26.COV2.S  
217 vaccine in the VAERS reports was 93, in excess of the incidences associated with the mRNA-  
218 1273 and BNT162b2 vaccines of 33 and 37, respectively, to a statistically significant degree ( $p <$   
219  $0.00001$  and  $p < 0.0001$ , respectively). The incidence of Bell's palsy associated with the  
220 BNT162b2 and mRNA-1273 vaccines in the VAERS reports was 37 for both, which exceeded the

### *COVID-19 Vaccines and Otologic Symptoms*

221 incidence of 36 associated with the Ad26.COV2.S vaccine, but not to a statistically significant  
222 degree.

223 These results were also clinically significant. The comparatively higher vertigo incidence rate  
224 of the Ad26.COV2.S vaccine implies that, had the 171 million people who received at least one  
225 vaccine dose over the study period all received the Ad26.COV2.S vaccine, rather than one of the  
226 assortment of Ad26.COV2.S, BNT162b2, and mRNA-1273 vaccines that was actually  
227 administered, there would have been 39,970 cases of vertigo over the two-day spike period, 9,209  
228 more than the 30,761 cases estimated to have actually occurred (an excess rate of about 1 per  
229 18,602 persons receiving at least one dose). Similarly, the vertigo incidence rate of the mRNA-  
230 1273 vaccine, which was elevated relative to the vertigo incidence rate of the BNT162b2 vaccine,  
231 implies that, had mRNA-1273 alone been administered, there would have been 33,183 cases of  
232 vertigo over the two-day spike period, 2,422 more than the 30,761 cases estimated to have actually  
233 occurred (an excess rate of about 1 per 70,733 persons receiving at least one dose). The  
234 comparatively higher tinnitus incidence rate of the Ad26.COV2.S vaccine implies that, had  
235 Ad26.COV2.S alone been administered, there would have been 1,471 cases of tinnitus over the  
236 two-day spike period, 498 more than the 973 cases estimated to have actually occurred (an excess  
237 rate of 1 per 344,028 persons receiving at least one dose). Finally, the comparatively higher  
238 hearing loss incidence rate of the Ad26.COV2.S vaccine implies that, had Ad26.COV2.S alone  
239 been administered, there would have been 435 cases of hearing loss over the one-day spike period,  
240 250 more than the 185 cases estimated to have actually occurred (an excess rate of 1 per 684,947  
241 persons receiving at least one dose).

242 IV. DISCUSSION



### *COVID-19 Vaccines and Otologic Symptoms*

265        This study created a novel way to compare the incidence of post-vaccine symptoms to  
266 published population incidence rates by using only cases with onset in the immediate one-to-two-  
267 day post-vaccination periods during which reported cases spike above expected cases to calculate  
268 incidence rates. In looking at VAERS reports of vertigo, tinnitus, hearing loss, and Bell’s palsy in  
269 recipients of COVID-19 vaccines, statistical evidence of an association of the vaccines with an  
270 excess of these cases appears at rates ranging from about 1 excess case per 5,500 vaccinated  
271 persons to about 1 excess case per 2.94 million vaccinated persons. Variations of this methodology  
272 might be helpful in investigating the risks of other vaccines.

*COVID-19 Vaccines and Otologic Symptoms*

273

VI. REFERENCES

- 274 1. Wichova H, Miller ME, Derebery MJ. Otologic Manifestations After COVID-19 Vaccination:  
275 The House Ear Clinic Experience. *Otol Neurotol*. Published online July 9, 2021.  
276 doi:10.1097/MAO.0000000000003275
- 277 2. Tseng P-T, Chen T-Y, Sun Y-S, Chen Y-W, Chen J-J. The reversible tinnitus and cochleopathy  
278 followed first-dose AstraZeneca COVID-19 vaccination. *QJM*. Published online July 23,  
279 2021. doi:10.1093/qjmed/hcab210
- 280 3. Parrino D, Frosolini A, Gallo C, Siatì RDD, Spinato G, Filippis C de. Tinnitus following  
281 COVID-19 vaccination: report of three cases. *Int J Audiol*. Published online June 13, 2021:1-  
282 4. doi:10.1080/14992027.2021.1931969
- 283 4. Formeister EJ, Chien W, Agrawal Y, Carey JP, Stewart CM, Sun DQ. Preliminary Analysis  
284 of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers  
285 for Disease Control and Prevention Vaccine Adverse Events Reporting System Data. *JAMA*  
286 *Otolaryngol Head Neck Surg*. 07 01, 2021;147(7):674-676. doi:10.1001/jamaoto.2021.0869
- 287 5. Data. VAERS. Accessed October 1, 2021. <https://vaers.hhs.gov/data.html>
- 288 6. Viele K, Berry S, Neuenschwander B, et al. Use of historical control data for assessing  
289 treatment effects in clinical trials. *Pharmaceutical Statistics*. 2014;13(1):41-54.  
290 doi:<https://doi.org/10.1002/pst.1589>
- 291 7. FAQs. VAERS. Accessed September 14, 2021. <https://vaers.hhs.gov/faq.html>
- 292 8. Berlin JA, Glasser SC, Ellenberg SS. Adverse Event Detection in Drug Development:  
293 Recommendations and Obligations Beyond Phase 3. *Am J Public Health*. 2008;98(8):1366-  
294 1371. doi:10.2105/AJPH.2007.124537

*COVID-19 Vaccines and Otologic Symptoms*

- 295 9. Miller ER, McNeil MM, Moro PL, Duffy J, Su JR. The reporting sensitivity of the Vaccine  
296 Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.  
297 *Vaccine*. 11 03, 2020;38(47):7458-7463. doi:10.1016/j.vaccine.2020.09.072
- 298 10. Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination  
299 reported to the Vaccine Adverse Event Reporting System, 1990-2016. *Journal of Allergy and*  
300 *Clinical Immunology*. 2019;143(4):1465-1473. doi:10.1016/j.jaci.2018.12.1003
- 301 11. Neuhauser HK. Epidemiology of vertigo. *Current Opinion in Neurology*. 2007;20(1):40-46.  
302 doi:10.1097/WCO.0b013e328013f432
- 303 12. FDA Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum  
304 (Moderna COVID-19 Vaccine/mRNA-1273). Published December 18, 2020.  
305 <https://www.fda.gov/media/144673/download>
- 306 13. FDA Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum  
307 (Pfizer-BioNTech COVID-19 Vaccine/BNT162b2). Published December 11, 2020.  
308 <https://www.fda.gov/media/144416/download>
- 309 14. FDA Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum  
310 (Janssen COVID-19 Vaccine/Ad26.COV2.S). Published February 27, 2021.  
311 <https://www.fda.gov/media/146338/download>
- 312 15. Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. *The Lancet Infectious*  
313 *Diseases*. 2021;21(4):450-452. doi:10.1016/S1473-3099(21)00076-1
- 314 16. Martinez C, Wallenhorst C, McFerran D, Hall DA. Incidence Rates of Clinically Significant  
315 Tinnitus: 10-Year Trend From a Cohort Study in England. *Ear and Hearing*. 2015;36(3):e69.  
316 doi:10.1097/AUD.0000000000000121



*COVID-19 Vaccines and Otologic Symptoms*

- 317 17. Neuhauser HK, Radtke A, von Brevern M, Lezius F, Feldmann M, Lempert T. Burden of  
318 Dizziness and Vertigo in the Community. *Arch Intern Med.* 2008;168(19):2118.  
319 doi:10.1001/archinte.168.19.2118
- 320 18. Alexander TH, Harris JP. Incidence of sudden sensorineural hearing loss. *Otol Neurotol.*  
321 2013;34(9):1586-1589. doi:10.1097/MAO.0000000000000222
- 322 19. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal  
323 generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiol Drug Saf.*  
324 2001;10(6):483-486. doi:10.1002/pds.677
- 325 20. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJW, Yuen N. Novel Statistical  
326 Tools for Monitoring the Safety of Marketed Drugs. *Clinical Pharmacology & Therapeutics.*  
327 2007;82(2):157-166. doi:<https://doi.org/10.1038/sj.clpt.6100258>
- 328 21. Eberth JM, Kline KN, Moskowitz DA, Montealegre JR, Scheurer ME. The Role of Media and  
329 the Internet on Vaccine Adverse Event Reporting: A Case Study of Human Papillomavirus  
330 Vaccination. *Journal of Adolescent Health.* 2014;54(3):289-295.  
331 doi:10.1016/j.jadohealth.2013.09.005  
332

## *COVID-19 Vaccines and Otologic Symptoms*

333

### VII. FIGURE LEGENDS

334 **Figure 1:** The Early-Onset Spike in VAERS Reports: All Adverse Events Reported to VAERS  
335 for All Vaccines, COVID-19 and Non-COVID-19, Administered between December 14, 2020 and  
336 June 7, 2021.

337 **Figure 2:** Triangle Venn Diagram Showing the Intersection of the Sets of Reports of Vertigo  
338 (V), Tinnitus (T), and Hearing Loss (H) in VAERS data.

339 **Figure 3:** Spike Periods for Otologic Symptoms: Reports to VAERS of (a) Vertigo, (b)  
340 Tinnitus, (c) Hearing Loss, and (d) Bell's Palsy in Relation to the COVID-19 Vaccines for Doses  
341 Administered between December 14, 2020 and June 7, 2021, Showing Spike Periods During  
342 Which Reported Cases Exceed Expected Cases. The solid line shows the number of cases reported  
343 and the horizontal dashed line shows the expected number of cases based on the population  
344 incidence rate. The vertical dotted line shows the number of days after dose administration at  
345 which the spike of reported cases above expected cases ends. The vertical axis is labeled in report  
346 numbers and the horizontal axis is labeled in the number of days between administration of the  
347 dose and symptom onset. An accuracy discount rate of 8% has been applied to all case counts, an  
348 underreporting multiplier of 3.3 has been applied to the tinnitus, hearing loss, and Bell's palsy case  
349 counts, and an underreporting multiplier of 166.9 has been applied to the vertigo case counts.

## Tables for “Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms”

Table 1: Overview of the Data Used in the Study.		
Study parameters	Period over which vaccinations included in the study were administered	December 14, 2020 to June 7, 2021
	Days after vaccination observed	30
	Days after vaccination during which adverse event reports were collected	60
<b>Vertigo<sup>1</sup> cases reported to VAERS (search term: “vertigo”)</b>	<b>Total cases</b>	<b>3,993</b>
	mRNA-1273	1,713
	BNT162b2	1,950
	Ad26.COVS.S	323
<b>Tinnitus<sup>2</sup> cases reported to VAERS (search terms: “tinnitus”; “hyposacusis”)</b>	<b>Total cases</b>	<b>6,562</b>
	mRNA-1273	2,615
	BNT162b2	3,366
	Ad26.COVS.S	573
<b>Hearing loss<sup>3</sup> cases reported to VAERS (search terms: “hearing loss”; “deafness”; “hyposacusis”)</b>	<b>Total cases</b>	<b>1,962</b>
	mRNA-1273	750
	BNT162b2	1,036
	Ad26.COVS.S	170
<b>Bell’s palsy<sup>4</sup> cases reported to VAERS (search terms: “bell’s palsy”; “facial palsy”; “facial paralysis”)</b>	<b>Total cases</b>	<b>3,541</b>
	mRNA-1273	1,463
	BNT162b2	1,824
	Ad26.COVS.S	248
<b>Overall vaccinated population (at least one dose)<sup>5</sup></b>	<b>Total</b>	<b>171,310,738</b>
	mRNA-1273	69,355,687
	BNT162b2	90,933,285
	Ad26.COVS.S	11,021,766

<sup>1</sup> Cases by manufacturer do not sum to total cases because the vaccine manufacturer was not identified in seven cases.

<sup>2</sup> Cases by manufacturer do not sum to total cases because the vaccine manufacturer was not identified in eight cases.

<sup>3</sup> Cases by manufacturer do not sum to total cases because the vaccine manufacturer was not identified in six cases.

<sup>4</sup> Cases by manufacturer do not sum to total cases because the vaccine manufacturer was not identified in six cases.

<sup>5</sup> The manufacturer figures have been scaled to equal the total number of first-doses reported by the CDC to have been administered. It is not clear why the manufacturer figures reported by the CDC do not sum to the total without scaling.

## Tables for “Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms”

Table 2: Comparing Spike Period Incidence Rates to General Population Incidence Rates. All incidence rates are annual per 100,000 persons.			
Symptom	Cases During Spike Period / Expected Cases for Spike Period / Spike Period (Days)	Incidence over Spike Period (95% CI) / General Population Incidence / Incidence over 21-Day Observation Period	z-statistic / p-value (two- tailed) / significant at the 95% confidence level?
Accuracy: 8%; Reporting Sensitivity/Multiplier: 30%/3.3 (vertigo: 0.6%/166.9); Overall: 28% (vertigo: 1,405%)			
Vertigo	30,760.64 / 13,141.65 / 2	3,276.98 (3,240.96, 3,313.00) / 1,400 / 554.47	154.78 / <0.00001 / <b>yes</b>
Tinnitus	972.94 / 506.89 / 2	103.65 (97.14, 110.16) / 54 / 18.06	20.71 / <0.00001 / <b>yes</b>
Hearing Loss	185.07 / 126.72 / 1	39.43 (33.75, 45.11) / 27 / 5.34	5.18 / <0.00001/ <b>yes</b>
Bell’s Palsy	346.06 / 215.90 / 2	36.87 (32.98, 40.75) / 23 / 9.27	8.86 / <0.00001 / <b>yes</b>
Accuracy: 8%; Reporting Sensitivity/Multiplier: 50%/2 (vertigo: 1%/100); Overall: 17% (vertigo: 845%)			
Vertigo	18,503.71 / 13,141.65 / 2	1,971.23 (1,943.11, 1,999.35) / 1,400 / 333.53	47.11 / <0.00001 / <b>yes</b>
Tinnitus	338.53 / 253.45 / 1	72.13 (64.45, 79.81) / 54 / 10.87	5.35 / <0.00001 / <b>yes</b>
Bell’s Palsy	122.44 / 107.95 / 1	26.09 (21.47, 30.71) / 23 / 5.58	1.40 / 0.16 / no
Hearing Loss	No spike period; reported cases never exceed expected cases, suggesting the absence of a positive association between hearing loss and the COVID-19 vaccines. Incidence over a 21-day observation period is 3.21 per 100,000 person-years.		

## Tables for “Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms”

Table 3: Proportional Reporting Ratios for Vertigo, Tinnitus, Hearing Loss, and Bell’s Palsy.					
Variable	(a) Cases after a COVID-19 vaccine dose	(b) Reports of all other adverse events after a COVID-19 vaccine dose	(c) Cases after all other non-COVID-19 vaccine doses	(d) Reports of all other adverse events after all other non-COVID-19 vaccine doses	PRR $\frac{\frac{a}{a+b}}{\frac{c}{c+d}}$ / $\chi^2$ statistic (1 df) / p-value / significant at the 95% confidence level?
Vertigo	3,993	458,837	9	4,955	4.76 / 14.13 / <0.001 / <b>yes</b>
Tinnitus	6,562	456,268	13	4,951	5.41 / 19.48 / <0.0001 / <b>yes</b>
Hearing Loss	1,962	460,868	8	4,956	2.63 / 2.66 / 0.103 / <b>no</b>
Bell’s Palsy	3,541	459,289	26	4,938	1.46 / 0.21 / 0.65 / <b>no</b>

## Tables for “Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms”

Table 4: Relative Incidence of Vertigo, Tinnitus, Hearing Loss, and Bell’s Palsy Associated with the mRNA-1273, BNT162b2, and Ad26.COVS COVID-19 Vaccines. All incidence rates are annual per 100,000 persons.					
Accuracy: 8%; Reporting Sensitivity/Multiplier: 30%/3.3 (vertigo: 0.6%/166.9); Overall: 28% (vertigo: 1,405%)					
Adverse event	Vaccine	Cases During Spike Period / Total Recipients over Full Observation Period	Incidence over Spike Period / General Population Incidence	Comparison with mRNA-1273 Vaccine: z-statistic / p-value (two-tailed) / Significant at the 95% confidence level?	Comparison with BNT162b2 Vaccine: z-statistic / p-value (two-tailed) / Significant at the 95% confidence level?
Vertigo	mRNA-1273	13,434.07 / 69,355,687	3,534.99 / 1,400	n/a	15.50 / <0.00001 / <b>yes</b>
	BNT162b2	14,684.73 / 90,933,285	2,947.17 / 1,400	n/i	n/a
	Ad26.COVS	2,571.58 / 11,021,766	4,258.07 / 1,400	8.81 / <0.00001 / <b>yes</b>	17.57 / <0.00001 / <b>yes</b>
Tinnitus	mRNA-1273	379.94 / 69,355,687	99.98 / 54	n/a	0.0 / 1.0 / no
	BNT162b2	497.53 / 90,933,285	99.85 / 54	n/i	n/a
	Ad26.COVS	94.63 / 11,021,766	156.70 / 54	3.88 / <0.001 / <b>yes</b>	3.99 / <0.0001 / <b>yes</b>
Hearing Loss	mRNA-1273	63.28 / 69,355,687	33.30 / 27	n/a	n/i
	BNT162b2	93.23 / 90,933,285	37.42 / 27	0.64 / 0.52 / no	n/a
	Ad26.COVS	28.00 / 11,021,766	92.72 / 27	4.56 / <0.00001 / <b>yes</b>	4.21 / <0.0001 / <b>yes</b>
“	“	“	“	“	Comparison with Ad26.COVS Vaccine: . . .
Bell’ s Palsy	mRNA-1273	139.15 / 69,355,687	36.62 / 23	n/a	0.0 / 1.0 / no
	BNT162b2	184.51 / 90,933,285	37.03 / 23	0.04 / 0.96 / no	0.05 / 0.96 / no
	Ad26.COVS	21.56 / 11,021,766	35.70 / 23	n/i	n/a

Figure 1: The Early-Onset Spike in VAERS Reports: All Adverse Events Reported to VAERS for All Vaccines, COVID-19 and Non-COVID-19, Administered between December 14, 2020 and June 7, 2021.




Figure 2: Triangle Venn Diagram Showing the Intersection of the Sets of Reports of Vertigo (V), Tinnitus (T), and Hearing Loss (H) in VAERS data.







Figure 3:

Spike Periods for Otologic Symptoms: Reports to VAERS of (a) Vertigo, (b) Tinnitus, (c) Hearing Loss, and (d) Bell's Palsy in Relation to the COVID-19 Vaccines for Doses Administered between December 14, 2020 and June 7, 2021, Showing Spike Periods During Which Reported Cases Exceed Expected Cases.



The solid line shows the number of cases reported and the horizontal dashed line shows the expected number of cases based on the population incidence rate. The vertical dotted line shows the number of days after dose administration at which the spike of reported cases above expected cases ends. The vertical axis is labeled in report numbers and the horizontal axis is labeled in the number of days between administration of the dose and symptom onset. An accuracy discount rate of 8% has been applied to all case counts, an underreporting multiplier of 3.3 has been applied to the tinnitus, hearing loss, and Bell's palsy case counts, and an underreporting multiplier of 166.9 has been applied to the vertigo case counts.